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not adequately controlled (NAC), not seizure free (NSF), seizure free (SF) and death. 
The length of each Markov cycle is 1 year for the whole study period. Patients could 
stay in the NAC state, move to the NSF or SF state, or die, according to the respective 
efficacy of each treatment. Utility values associated with each health state were 
used to estimate the number of QALYs associated with each treatment. Analyses 
were conducted from both a Canadian Ministry of Health (MoH) and a societal 
perspective. Results: Compared with VPA+CLB, STP+VPA+CLB was associated 
with incremental cost-effectiveness ratios of CAD$50,122/QALY from a MoH per-
spective and was dominant from a societal perspective. Results of the probabilistic 
sensitivity analysis indicated that the ICUR remained below CAD$100,000 in 98.4% 
and in 100% of the simulations from a MoH and a societal perspective respec-
tively. ConClusions: This economic evaluation demonstrates that STP+VPA+CLB 
is a cost-effective strategy as adjunctive therapy in patients with SMEI whose sei-
zures are not adequately controlled with VPA+CLB alone.
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HosPital-BaseD UtilizatioN iN PatieNts WitH atyPical Hemolytic 
Uremic syNDrome
Belk K.W., Craver C.W.
MedAssets, Charlotte, NC, USA
objeCtives: Atypical hemolytic uremic syndrome (aHUS) is a rare genetic disease 
affecting kidney function that predominantly affects children. The objective of this 
study was to evaluate hospital-based utilization in patients with aHUS. Methods: 
A retrospective cross-sectional study was conducted on 6571 aHUS discharges in 
the MedAssets health system data for inpatient (IP) and outpatient (OP) visits for 
the January 2009 to December 2013 timeframe. Age and gender, hospital charac-
teristics, clinical comorbidities and measures of utilization including number of 
visits and length of stay (LOS) were described. Multivariable regression was used 
to identify significant drivers of hospital-based utilization. Results: The sample 
included 2089 patients with more than 76.0% of the hospital visits occurring in 
the outpatient setting. The mean age of the sample was 23 years with 59.3% under 
the age of 18 and 61.0% female. More than 60% of the visits occurred in teaching 
facilities and facilities with 300 beds or more. Among inpatient admissions, the 
average LOS was 16.02 days with the most common procedures being packed 
cell transfusions (41.7%) therapeutic plasmapheresis (29.8%) and serum transfu-
sion (17.4%). Same-hospital readmissions occurred in 14.5% of the inpatient sam-
ple. Comorbidities for this population included renal disease (56.2%), congestive 
heart failure (11.1%), chronic pulmonary disease (10.0%) and diabetes without 
chronic complications (8.0%). Cardiovascular disease (2.8 days, p< .001), rheumatic 
disease (2.5 days, p< .05), and malignancy (4.2 days, p< .0001) were significantly 
associated with longer inpatient LOS. ConClusions: Patients with aHUS con-
sume a significant amount of health care resources. Further research is required 
to understand the effect of interventions/treatments on mitigating the progress 
of this disease.
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HealtH statUs, HealtH care resoUrce Use, aND treatmeNt 
satisfactioN iN PatieNts WitH Partial oNset seizUres (Pos) iN tHe 
UNiteD states
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objeCtives: As of December 2013, there were over 20 drugs available in the US for 
the treatment of POS. The aim of this study is to understand the remaining burden of 
disease and the need for newer treatments. Methods: Data from the 2012 and 2013 
U.S. National Health and Wellness Survey (NHWS) was analyzed. The NHWS is self-
administered, internet-based survey of a nationwide sample of adults (18+ years) 
stratified to represent the demographic composition of the U.S. population. Patients 
self-reported a diagnosis of epilepsy with POS and were grouped as uncontrolled (> = 
1 seizure per month) and controlled (< 1 seizure per month). Patients provided infor-
mation on health status (mental (MCS), physical component summary (PCS), and 
SF-6D (health utility) scores from the SF-36v2), resource utilization in the past six 
months and treatment satisfaction with current epilepsy prescription medication (1 
[extremely dissatisfied] to 7 [extremely satisfied]). Regression modeling controlled 
for covariates. Results: Among 207 diagnosed epilepsy with POS patients, 38.6% 
were uncontrolled and 61.4% were controlled. Uncontrolled vs. controlled patients 
were similar in age, gender and ethnicity, but were more likely to be in a commit-
ted relationship, less educated, and employed (p< 0.05). Uncontrolled vs. controlled 
patients had lower health utilities (0.66 vs. 0.70, p= 0.015), MCS scores (43.05 vs. 47.10, 
p= 0.008), and non-significant PCS scores (47.95 vs. 49.12, p= 0.371). Uncontrolled vs. 
controlled patients reported more emergency room visits (207.7%, p= 0.002), hospi-
talizations (447.9%, p< 0.001), and traditional provider visits were non-significantly 
greater (22.8%, p= 0.197). Amongst treated patients, treatment satisfaction was lower 
for uncontrolled vs. controlled (5.27 vs. 5.86, p= 0.01). ConClusions: Despite the 
availability of existing anti-epileptic drugs (AED) in 2013, the results suggest a sig-
nificantly higher economic and humanistic burden in patients with uncontrolled 
seizures. POS patients are very much in need of additional treatment options for 
which newer AEDs may provide a solution.
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bACkgRound: MS is known to be a costly and intensive condition to treat which 
allows for an opportunity to better understand how non-clinical factors can impact 
costs and other economic measures. objeCtives: To observe and report variances 
respectively. Thus, delayed-release dimethyl fumarate was dominant (had lower 
costs and higher QALYs gained) compared to glatiramer acetate and fingolimod. 
Sensitivity analyses showed that delayed-release dimethyl fumarate was less 
costly and more effective than glatiramer acetate and fingolimod for most of the 
input parameter values and assumptions tested. ConClusions: Delayed-release 
dimethyl fumarate, a new oral drug indicated for RRMS, is a cost-effective treat-
ment when compared to glatiramer acetate and fingolimod. Sensitivity analyses 
support the robustness of the model results.
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cost effectiveNess stUDy of tetraBeNaziNe tHeraPy of cHorea 
associateD WitH HUNtiNgtoN’s Disease
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objeCtives: Evaluate the cost effectiveness of Tetrabenazine for the treatment 
of chorea in Mexican patients with Huntington disease versus current therapy, 
from a governmental perspective. Methods: Cost-effectiveness and a cost utility 
analysis were done. Effectiveness measurements were: percentage of successful 
patients treated and QALYs. Disease-specific utility values assigned to each disease 
state, have been estimated by Mevhibe 2009 using instrument Huntington’s disease 
health-related quality of life questionnaire, and expert opinion. Costs considered are 
direct medical care, drug, adverse events. Analysis used a governmental perspective 
(Mexican Institute of Social Services costs). The model contains four arms, one for 
each alternative to compare: tetrabenazine, olanzapine, haloperidol and risperidone. 
A Markov model was performed considering 80 weeks horizon with 1 week cycles 
simulating Mexican population with the proposed treatment alternatives. Finally a 
univariated probabilistic sensitivity analysis was done to validate consistency in the 
model. Results: Tetrabenazine generated the lowest cost per patient ($3,728USD), 
followed by risperidone ($ 4,632USD), haloperidol ($4,790USD), the alternative that 
generates the largest cost is olanzapine ($4,954) (conversion rate: USD= 13.1 MxPesos. 
Average 2013). In terms of effectiveness, we find that tetrabenazine arm has the 
highest proportion of successful treatments regarding their comparators (56.0%, 
95% CI: 46.0 - 65.0%), as well as a greater number of QALYs gained (QALY 1.166, 95% 
CI: 1130-1203) ConClusions: The use of tetrabenazine itself can be considered a 
cost-effective from the perspective of dominant institutions of public health inter-
vention in Mexico, since it is a less expensive and more effective strategy regarding 
its comparators.
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ePilePtic seizUres
Hatswell A.1, Anelli M.2, Vigevano F.3, Saunders A.4, Bullement A.1, Lee D.1
1BresMed, Sheffield, UK, 2Keypharma srl, Milan, Italy, 3Bambino Gesù Children’s Hospital, Rome, 
Italy, 4Bioexcel Limited, Oxford, UK
objeCtives: Buccolam (licensed midazolam oromucosal solution) is indicated in 
prolonged, acute, convulsive seizures (PACS) in pediatric patients. Clinical data con-
firm that midazolam oromucosal solution is at least as effective as existing treat-
ments. Current-care in Italy for community PACS is rectal diazepam, which carers 
are often reluctant to use due to social acceptability issues. The aim of this study was 
to establish whether use of Buccolam could affect the cost of treatment. Methods: 
A decision-tree model was developed to perform cost-minimisation analysis com-
paring Buccolam and rectal diazepam for the treatment of PACS in children initially 
occurring in the community setting. The model captures the treatment pathway for 
children experiencing a PACS including whether treatment is administered in the 
community, whether an ambulance is required and whether the patient is hospi-
talised. Costs were taken from Farmadati Italia and official DRGs. Efficacy estimates 
were taken from published literature whereas, due to a lack of available evidence, 
effectiveness was estimated by a 4-round Delphi-panel process consisting of leading 
Italian clinicians. Results: Over one year, compared to rectal diazepam, Buccolam 
showed a reduction in per patient costs of € 1,765 from an INHS perspective. The 
largest saving came from an estimated reduction in inpatient costs: € 1,677 per 
patient per year. Estimates of budget impact over five years varied from a saving 
of € 76 million to over € 152 million when low and high-case population estimates 
were used. ConClusions: Treatment with Buccolam is estimated to be cost sav-
ing, through a reduction in the need for ambulance call-outs and hospital stays. 
Treatment with Buccolam is expected to increase the number of PACS resolved in 
the community through increased carer willingness to treat seizures and fewer 
failed deliveries: Buccolam has a more acceptable method of administration that 
avoids compromising patients’ dignity and an easier administration route com-
pared to diazepam.
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cost-effectiveNess of stiriPeNtol iN tHe treatmeNt of severe 
myocloNic ePilePsy iN iNfaNcy iN caNaDa
Lachaine J., Lambert-Obry V.
University of Montreal, Montreal, QC, Canada
objeCtives: Severe myoclonic epilepsy in infancy (SMEI, Dravet Syndrome) is a 
severe type of pharmacoresistant epilepsy, characterized by repeated and prolonged 
generalized seizures. Patients with SMEI show important delays in psychomotor 
and cognitive development that often progress in eventual mental retardation. 
Stiripentol (STP) has been approved in Canada for use in conjunction with valproate 
(VPA) + clobazam (CLB) as adjunctive therapy in patients with SMEI whose seizures 
are not adequately controlled with VPA+CLB alone. The objective of this study was 
to assess, from a Canadian perspective, the economic impact of STP+VPA+CLB com-
pared with VPA+CLB in the treatment of SMEI. Methods: The cost-effectiveness of 
STP+VPA+CLB compared to VPA+CLB in the treatment of SMEI was assessed over 
a 5-year horizon using a Markov model. The model comprises four health states: 
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HealtH care resoUrce UtilizatioN aND meDical costs iN PatieNts 
WitH mUltiPle sclerosis
Yermakov S.1, Davis M.1, Calnan M.1, Fay M.2, Duh M.1, Iyer R.3
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objeCtives: Prior studies have compared multiple sclerosis (MS) patients who are 
adherent to disease-modifying drug (DMD) therapy with those who are not, but have 
not analyzed the effect of varying levels of adherence on patient outcomes. This study 
characterized the benefits and cost offsets of increasing adherence to DMDs. Health 
care costs and resource use were assessed for patients with different adherence levels 
at various periods following DMD initiation. Methods: A retrospective analysis was 
conducted using OptumHealth Reporting and Insights employer claims database 
on MS patients (≥ 2 diagnoses of ICD-9-CM 340.xx) initiating DMD therapy in 2002 
through Q1 2012. Direct medical costs (reimbursements to providers), indirect costs 
(disability payments and employer workloss costs), and resource use were analyzed 
in the six months prior to (baseline) and up to 36 months following (observation 
period) initiation. Adherence, persistence, and other outcomes were measured at 6, 
12, 24, and 36 months, and stratified by DMD adherence level. Results: 1,538 patients 
met the selection criteria (baseline age 43.6 years, 63% female). Adherence measured 
by proportion of days covered (PDC) declined from 82% at 6 months to 67% at 36 
months following initiation (medication possession ratio of 79% over the observation 
period). By 36 months, 42% of patients had discontinued DMD therapy; 22%, 31%, and 
47% of patients had PDC< 40%, 40% to 79%, and ≥ 80%, respectively. Non-DMD direct 
costs ($36,119, $30,277, and $25,886) and indirect costs ($23,194, $16,872, and $13,568) 
decreased substantially with higher adherence (PDC< 40%, 40% to 79%, and ≥ 80% at 36 
months, respectively). Higher adherence was also associated with lower all cause and 
MS-related inpatient admissions and emergency visits. Similar trends were observed 
at each follow-up period. ConClusions: This study shows higher adherence to DMD 
therapies is associated with lower non-DMD medical and indirect costs and decreased 
health care resource use for MS patients.
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aDHereNce of mUltiPle sclerosis PatieNts to Disease moDifyiNg 
treatmeNt aND its imPact oN QUality of life
Apecechea de Scheffer M., Faber S., Potthoff P., Eichmann F.
Kantar Health Germany, Munich, Germany
objeCtives: Disease-modifying therapies (DMT) play an important part in the 
treatment of Multiple Sclerosis (MS). Non-Adherence to DMT affects therapy suc-
cess and thereby disturbs Health Related Quality of Life. The present study inves-
tigates patient adherence to approved DMTs for MS among geographically and 
culturally diverse patient populations and their impact on health related quality of 
life. Methods: The study was an observational multinational post marketing study. 
2,566 patients 18 years or older with a documented diagnosis of relapsing-remitting 
MS (RRMS) and monotherapy with current DMT from Argentina, Australia, Austria, 
Belgium, Brazil, Canada, Czech Republic, Denmark, France, Germany, Iran, Ireland, 
Israel, Italy, Mexico, The Netherlands, Portugal, Spain, Sweden, Switzerland, UK, and 
Venezuela were included. Retrospective medical data about diagnosis and therapy 
were documented by physicians or nurses. For the purpose of patient reported 
outcome assessment, the MS International Quality of Life Questionnaire (MusiQoL) 
was selected. Results: “Adherence” was operationally defined as: “Not missing a 
DMT injection or changing dose within 4 week prior to study”. The study findings 
revealed that 75.0% of the patients were adherent. 12.6% of all patients forgot to 
administer injections compared to 50% of non-adherent patients.The most com-
mon reasons for non-adherence were forgetting to administer the injection, being 
tired of taking injections, pain at injection, and injection anxiety. Compared to non-
adherent patients, the disease history of adherent patients showed shorter disease 
duration (adherent: median 6 years; non-adherent: Median 7 years.), significantly 
shorter treatment time (30 months vs. 36 months; p< .001) and a better MusiQoL 
score (18.0 vs. 22.0; p< .001). ConClusions: Non-adherence to DMTs affects QoL 
of MS-Patients. Special attention should be given to the causes for non-adherence. 
Reminder systems for injections can overcome the most frequent reason for non-
adherence.
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Smalarz A.1, Prado M.2
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objeCtives: MS is a chronic, progressive, autoimmune disease that is characterized 
by episodes of worsening symptoms or relapses. Patient adherence to medications 
can help reduce or lessen relapses; however, non-adherence is a recognized problem 
in patients with MS. The objectives of this study are to better understand patients’ 
reason(s) for switching and/or not being adherence to their medications. Methods: 
We extracted 150 records for MS patients from a unique database of physician-
patient interactions (RealHealth Data). Using Atlas.ti, we analyzed these records to 
uncover trends for medication switches and/or non-adherence, i.e., when, why and 
how patients stopped, what if anything they took as a replacement or an addition as 
well as to the patients’ reaction(s) to new medication or non-medication. Results: 
On average, patients’ ages ranged from 18-45, 66% of patients reported their pain as a 
6 or 8 (on a scale out of 10) and 72% reported actively taking supplements in addition 
to their prescribed medications. Patients’ functional disability was similar to the 
general MS population, with a noted variability of motor skills. The medications pre-
scribed to these patients included: Aubagio (3%), Copaxone (22%), Extavia/Betaseron 
(15%), Gilenya (17%), Rebif (14%), Tecfidera (10%) and Tysabri (19%). Patients’ reported 
in health care consumed for the treatment of multiple sclerosis (MS) in patients 
enrolled in private (commercial) and publicly (Medicaid) funded health insurance 
programs. Methods: In a retrospective analysis, integrated medical and phar-
macy claims data were analyzed to select patients with a diagnosis of MS (ICD-9 
code 340) during 2012 calendar year. The presence of comorbidities was also deter-
mined using ICD-9 codes present on medical claims. Prescription drug use was 
evaluated by pharmacy claims and drug-specific billing codes Results: 19,984 
patients with MS were identified, 18,269 from commercial payers and 1715 from 
Medicaid. Patients in the Medicaid group were younger (44.4 vs 48.8 years) and 
female (81.5% vs. 76.8%) compared to Commercial group, respectively. Although 
total annual costs related to the care of MS for the groups reflected a modest differ-
ence ($31,107 commercial; $33,344 Medicaid), costs associated with specific service 
categories varied greatly. Pharmacy costs were considerably less in the Medicaid 
group; however inpatient and emergency room costs were as much as 5 times 
higher. The lower pharmacy costs in the Medicaid group are related to lower use of 
disease-modifying treatments (DMTs); overall use of DMTs in the Medicaid group 
was seen in 32.5% of patients; while in the commercial patient group was 52.1%. 
Multivariate regression will be performed to examine the differences in cost and 
utilization adjusting for differences in baseline characteristics. ConClusions: 
This analysis illustrates that notable variances exist in consumption of health care 
resources between patients enrolled in privately and publically funded health care 
programs. These variances may have additional implications relating to outcomes 
specific to MS.
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bACkgRound: Multiple studies have demonstrated the benefits of DMTs in slow-
ing disease progression; however cost of the DMTs is an issue given the current 
pricing pressures. This study evaluates the comparison of HRU and associated cost 
to provide the overall economic benefits of treatment with DMTs. objeCtives: To 
compare populations, costs, and health care resource utilization (HRU) in patients 
with MultipleSclerosis (MS) treated with a disease modifying therapy (DMT) versus 
those who were not (Non-DMT). Methods: A retrospective analysis of integrated 
medical and pharmacy claims data were analyzed inpatients with a diagnosis of 
MS (ICD -9 of 340.0) during 2012. There were 2 cohorts, those treated with a DMT 
and those not treated, (Non-DMT) for the entire 12 months by the presence or 
absence of relevant NDC and HCPCS codes. Results: 10,876 patients comprised 
the DMT cohort compared to 25,431 in the Non-DMT cohort. The two study groups 
were similar across a number of demographic variables including gender and age. 
When comparing HRU, significant differences were found in the DMT vs. Non-DMT 
treated groups. The unadjusted analysis showed that there was a 39.2% reduction 
in ER visits (15.68/100 vs. 24.25/100), a 35.9% reduction in MS related hospitaliza-
tions (46.64/100 vs. 76.62/100) and a 15.6% reduction in hospitalization length of 
stay (5.14 vs. 6.09), respectively. The average cost per patient for the DMT treated 
group was $61,698.16 ($33,983.87 due to DMT cost) compared to the total average 
cost per patient of $43,772.72 in the Non-DMT treated group. Multivariate regres-
sion will be performed to examine differences in cost and utilization adjusting for 
differences in baseline characteristics. ConClusions: Although the total costs of 
treatment in the DMT group were substantially higher than in the Non-DMT group 
as expected, we found significantly beneficial reductions in HRU use that are costly 
drivers in health care.
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Drivers of UtilizatioN amoNg PatieNts WitH mUcoPolysaccHariDosis 
iN tHe HosPital settiNg
Belk K.W., Craver C.W.
MedAssets, Charlotte, NC, USA
objeCtives: Mucopolysaccharidosis (MPS) is a rare metabolic disorder with a wide 
spectrum of symptoms affecting the bone, skeletal system, and organs of affected 
individuals. The severity of symptoms varies widely. The objective of this study is 
to examine drivers of hospital utilization in MPS patients. Methods: A retrospec-
tive descriptive study was conducted on a cross-section of MPS discharges in the 
MedAssets health system data for inpatient (N= 527) and outpatient (N= 10450) 
visits from 2009 through 2013. Negative binomial multivariable regression was 
used to identify significant drivers of inpatient and outpatient visits and inpatient 
length of stay (LOS). Results: The sample included 1454 unique patients from 216 
hospitals. More than half of thedischarges (66.7%) were male with 87.3% less than 
18 years old and 8.7% between the ages of 18 and 29. The most common comorbid 
conditions in inpatients were chronic obstructive pulmonary disease (27.1%), res-
piratory failure (24.1%), pneumonia (20.5%), heart valve disorders (18.6%), epilepsy 
and seizures (17.8%), and hypertension (16.1%). In outpatients the most common 
comorbidities were delayed mental development (7.9%), musculoskeletal disor-
ders (6.9%), hypertension (6.9%), and heart valve disorders (5.7%). The average 
number of outpatient visits was 7.1 with primary drivers including esophageal 
reflux (IRR= 1.73, p< .001), lack of development (IRR= 1.69, p< .001), gastrointestinal 
issues (IRR= 1.47, p< .01), and hydrocephalus (IRR= 1.52, p< .05). While the average 
number of inpatient visits was less than 1 the average LOS was 11.47. Respiratory 
failure (IRR= 1.58, p< .001) and vein disorders (IRR= 1.71, p< .01) were associated 
with inpatient visits. In addition to teaching status and region drivers of LOS were 
hypertension (IRR= 1.64, p< .001), respiratory failure (IRR= 1.50, p< .01), cardiovas-
cular disorders (IRR= 3.91, p< .01), pneumonia (IRR= 1.40, p< .05), and vein disorders 
(IRR= 1.71, p< .05). ConClusions: MPS patients average more than one outpatient 
visit per year and when hospitalized have long LOS. Drivers of utilization vary in 
the inpatient and outpatient setting.
